Advanced Therapies Week opens the year for the cell and gene therapy manufacturing audience. It reaches close to the same modality-specific crowd as the spring and fall advanced-therapy shows, but lands early enough to shape a seller's plan for the rest of the year.
What Advanced Therapies Week is
Run by Phacilitate, Advanced Therapies Week focuses on cell and gene therapy manufacturing, commercialization, and investment. Its audience is weighted toward advanced-therapy developers, the CDMOs and contract manufacturers that produce cell and gene therapies, analytical and tools vendors, and investors focused on the space. Compared with a scientific meeting like ASGCT, it leans further toward manufacturing, commercialization, and business-development conversations.
The GTM signal at Advanced Therapies Week
Exhibiting here is a sharp, modality-specific signal: the audience filter to cell and gene therapy is already done, so a booth means budget committed to visibility in front of exactly that crowd. A named speaker tied to a specific program or capability is an equally sharp contact-level hook. Because the show sits early in the year, presence is also an early read on which accounts are actively investing in the modality this cycle, ahead of the later shows. See selling around life science conferences for how to weigh the three signals.
The outreach window
Exhibitor and speaker lists become public ahead of the January event, giving a window to cross-reference the roster against your cell and gene therapy account list and plan specific outreach before the show opens. Because it lands at the start of the year, it doubles as a planning input: the accounts visible here are a useful shortlist to carry into the spring and fall advanced-therapy shows. On-site outreach works as a fallback, and the post-show window holds for a few weeks while a reference to a specific conversation is still fresh.
Who this matters most for
A CDMO with cell and gene therapy manufacturing capability should treat Advanced Therapies Week as an early-year priority, since the audience is a near-direct match for that buyer. A tools or services vendor serving advanced-therapy workflows will find a tight fit here. A CRO running cell and gene therapy trials can use it as an early read on active programs for the year ahead.